

KATHLEEN D. GIBSON, MD
1135 116th Ave NE, Suite 305
Bellevue, WA 98004
(425) 453-1772

PERSONAL

Born in Lafayette, Indiana; October 26, 1966

EDUCATION

Endovascular Fellowship: Kaiser Permanente Hospital
Honolulu, HI; October-December 2001

Fellowship: University of Washington School of Medicine
Vascular Surgery, June 1999-June 2001

Residency: University of Washington School of Medicine
General Surgery; 1994-June 1999

MD: University of Washington School of Medicine
Seattle, WA; September 1990-June 1994

BS: University of Washington
Seattle, WA
Major: Chemical Engineering
September 1985-December 1989

PROFESSIONAL EXPERIENCE

Vascular Surgeon
Partner, Lake Washington Vascular Surgeons PLLC
Bellevue and Kirkland, WA
Privileges held at:
Overlake Hospital Medical Center, Bellevue, WA
Evergreen Hospital Medical Center, Kirkland, WA
July 2001-present

Chief of Surgery
Overlake Hospital Medical Center, Bellevue, WA
September 2005-December 2007

BOARD POSITIONS

Overlake Hospital Medical Center Board of Directors
Board Member At-large, July 2010-January 2013

American College of Phlebology
Board of Directors, July 2014-present

American Board of Venous and Lymphatic Medicine
Board of Directors, September 2015-present

BOARD CERTIFICATION

American Board of Surgery
February 2000, September 2011

American Board of Surgery, Vascular Surgery
May 2002, November 2011

STATE LICENSURE

1994-present Washington State MD 0036183
2001-present State of Hawaii MD 11532

COMMITTEES AND EDITORIAL BOARDS

2016 American College of Phlebology: Annual Program Chair
2016-present American Venous Forum, Bylaws Committee
2015-present American Board of Venous and Lymphatic Medicine: Question
Writing Committee
2015-present Medical Advisor, Vein Magazine
2014-present American College of Phlebology: Guidelines Committee
2014-present American College of Phlebology: Scientific Committee
2014-present Vein Magazine: Medical Advisory Board
2013-present European Journal of Vascular and Endovascular Surgery: Selected
Reviewer
2013-present American Board of Surgery: Vascular Surgery Qualifying Exam
Committee
2013-present Society for Vascular Surgery: VESAP Writing Committee

- 2013-2015 American Venous Forum : Vascular Fellow’s Education Committee, 2014 Chair
- 2013-present American Venous Forum: Membership Committee, 2016 Chair
- 2013-present American College of Phlebology: ACCME Committee
- 2013-present Phlebology: Selected Reviewer
- 2013-present European Journal of Vascular Endovascular Surgery: Selected Reviewer
- 2011-present Journal of Vascular Surgery: Selected Reviewer
- 2007-2010 Western Vascular Society: Membership Committee
- 2009, 2014 American College of Phlebology: Program Committee

PUBLICATIONS

Gibson K, Schul M, Meissner M, Khilnani N. “American College of Phlebology Guidelines-Treatment of Refluxing Accessory Saphenous Veins.” *Phlebology*, 2016 Oct (epub ahead of print)

Kolluri R, Gibson K, Cher D, Madsen M, Weiss R, Morrison N. “Roll-in phase analysis of clinical study of cyanoacrylate closure for incompetent great saphenous veins.” *J Vasc Surg Venous Lymphat Disord*. 2016 Oct;4(4):407-15.

Gibson K, “Incorporating nontumescent ablation into your practice.” *Endovascular Today*, 2016 July; 75-78.

Gibson K, Ferris B, “Cyanoacrylate Closure of Incompetent Great, Small and Accessory Saphenous Veins without the use of Post-Procedure Compression: Initial Outcomes of a Post-Market Evaluation of the VenaSeal System (the WAVES Study).” *Vascular* 2016 May 20 (epub ahead of print)

Gibson K, “Tips and tricks for the diagnosis and management of vulvar varicose veins.” In Allegra C, Antignani P, Kalodiki E, editors: *Tips and tricks in angiology*. Turin: Edizioni Minerva Medica; 2016. ISBN:978-88-7711-868-4.

Gibson K, Kabnick L, "A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Varithena® (Polidocanol Endovenous Microfoam 1%) for Symptomatic, Visible Varicose Veins With Saphenofemoral Junction Incompetence." *Phlebology*, March 2016. Epub ahead of print

Gibson K, Tabah A. "Clinical evidence behind the Venaseal™ Closure System." *Endovascular Today*, 2015 July; 33-35.

Meissner M, Gibson K. "Clinical outcome after treatment of pelvic congestion syndrome: sense and nonsense." *Phlebology* 2015 Mar;30(1 Suppl): 73-80.

Morrison N, Gibson K, McEnroe S, Goldman M, King T, Cher D, Jones A. "Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent saphenous veins (VeClose)." *J Vasc Surg*. 2015 Apr;61(4):985-94.

Chi YW, Schul M, Gibson K, Rosenblatt M, Kabnick L, Jaff M. Chronic venous disorder registry: a new perspective." *Phlebology* 2013: May 3;29(7):415-247.

Rathbun S, Norris A, Morrison N, Gibson K, Raymond-Martimbeau P, Worthington- Kirsch R, Hohenwarter E, Lohr J, McLafferty R, Stoner J. "Performance of endovenous foam sclerotherapy in the USA for the treatment of venous disorders: ACP/SVM/AVF/SIR quality improvement guidelines." *Phlebology* 2013: Feb 6 (epub ahead of print).

Gibson K, Wright D, Meissner M. "Great saphenous vein (GSV) diameter does not correlate with worsening quality of life scores in patients with GSV incompetence," *J Vasc Surg*. 2012 Dec;56(6):1634-41.

Rathbun S, Norris A, Morrison N, Gibson K, Hohenwarter E, Lohr J, Raymond-Martimbeau P, Worthington-Kirsch R, Stoner J. "Performance of the endovenous foam sclerotherapy in the USA," *Phlebology*, March 2012; 27(2):59-66

Wise M, Klein D, Gibson K. "Isolated Superficial Femoral Artery Aneurysm: A Case Study," *J Vasc Ultrasound*. 2012;36(1):42-44.

Regan J, Gibson K, Rush J, Shortell C, Hirsch S, Wright D. "Clinical significance of cerebrovascular gas emboli during ploidocanal endovenous ultrasound: correlation with magnetic resonance imaging in patients with right-to-left shunt," *J Vasc Surg*, January 2011; 53(1):131-7.

Wright D, Gibson K, Barclay J, Razumovsky A, Rush J. "High prevalence of right-to-left shunt in patients with symptomatic great saphenous incompetence and varicose veins," *J Vasc Surg*, January 2010; 51:104-7.

Gibson K, Ebert A. "Preoperative Vein Mapping," Strandness's Duplex Scanning in Vascular Disorders Fourth Ed., Philadelphia: Lippincott Williams & Wilkins, 2010; 231-234.

Gibson K, Ebert A. "Venous Ablation Procedure," Strandness's Duplex Scanning in Vascular Disorders Fourth Ed., Philadelphia: Lippincott Williams & Wilkins, 2010, 235-239.

Wise M, Gibson K. "Bilateral Superficial Temporal Artery Aneurysms," Journal for Vascular Ultrasound. 2009 Dec;33(4):192-194

Gibson K, Ferris B, Pepper D. "Foam sclerotherapy for the treatment of superficial venous insufficiency," Surg Clin North Am. 2007 Oct;87(5):1285-95.

Gibson K, Ferris B, Pepper D. "Endovenous laser treatment of varicose veins.," Surg Clin North Am. 2007 Oct;87(5):1253-65.

Gibson K, Ferris B, Polissar N, Neradilek B, Pepper D, "Endovenous Laser Treatment of the Small Saphenous Vein: Efficacy and Complications," J Vasc Surg. 2007 Apr;45(4):795-801

Guerro A, Gibson K, Kralovich KA, Pipinos I, Agnostopoulous P, Carter Y, Bulger E, Meissner M, Karmy-Jones R. "Limb loss following lower extremity trauma: what can be done proactively?" Injury, November 2002;33(9):765-9.

Gibson K, Gillen D, Caps M, Kohler T, Sherrard D, Stehman-Breen C. "Vascular Access Survival and Incidence of Revisions: A Comparison of Prosthetic Grafts, Simple Autogenous Fistulas, and Venous Transposition Fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study," Journal of Vascular Surgery, October 2001; 34(4):694-700.

Gibson K, Kohler T, Stehman-Breen C. "Use of the Vascular Diagnostic Laboratory in Improving the Success of Angioaccess Procedures." Semin Vasc Surg, September 2001; 14(3):222-6.

Gibson K, Caps M, Bergelin R, Primozich J, Strandness DE, Jr. "Identification of Factors Predictive of Lower Extremity Vein Graft Thrombosis," Journal of Vascular Surgery, January 2001; 33(1):24-31

Gibson K, Strandness DE, Jr. "Carotid Endarterectomy Without Arteriography," Current Techniques in Vascular Surgery, New York: McGraw-Hill, 2000; 1-13.

Gibson K, Meissner M, "Deep Venous Thrombosis," Conn's Current Therapy 2001 Ed., Philadelphia, W.B. Saunders Co, 2001; 359-365.

Gibson K, Caps M, Gillen D, Aldassy M, Kohler T, Hatsukami T, Sherrard D, Stehman-Breen C. "Assessment of a Policy to Reduce the Placement of Prosthetic Hemodialysis Access in a Veterans Health Care System," *Kidney International*, June 2001, 59(6):2335-45.

Karmy-Jones R, Wilson M, Cornejo C, Wilson M, Gibson K, Engram L, Meissner M, "The Surgical Management of Cardiac Arrest Due to Massive Pulmonary Embolus in Trauma Patients," *Journal of Trauma*, March 2000; 48(3):519-20

McLanahan D, King LT, Weems C, Novotney M, Gibson K, "Retrorectus Prosthetic Mesh Repair of Midline Abdominal Hernia," *American Journal of Surgery*, May 1997; 173(5):445-9.

van-Belle G, Gibson K, Nochlin D, Sumi M, Larson EB, "Counting Plaques and Tangles in Alzheimer's Disease: Concordance of Technicians and Pathologists." *Journal of the Neurological Sciences*, February 12, 1997; 145(2):141-6.

SELECTED INVITED LECTURES/PRESENTATIONS

“Duration of Treatment in the management of Acute DVT”, Gibson K, VERVE Symposium, Sydney, Australia, December 2, 2016

“Vulvar Varicose Veins: Controversies in Management and Treatment”, Gibson K, VERVE Symposium, Sydney, Australia, December 1, 2016

“Creating WAVES: First US Post Market Results using Venaseal Closure System without Compression”, Gibson K, VEITH Symposium, New York, NY November 17, 2016

“Challenges of Implementing Proprietary Foam into Practice: It’s a different kind of Practice Model”, Gibson K, VEITH Symposium, New York, NY November 17, 2016

“Nontumescent technologies: The results are good, why aren’t they being reimbursed?”, Gibson K, AIM Symposium, New York, NY, November 16, 2016

“Perforator Veins: Pathophysiology and Management”, Gibson K, AIM Symposium, New York, NY, November 16, 2016

“Cyanoacrylate Closure of Incompetent Great, Small and Accessory Saphenous Veins without the use of Post-Procedure Compression: Initial Outcomes of a Post-Market Evaluation of the VenaSeal System (WAVES trial)-Three Month Data”, Gibson K, ACP Annual Congress, Anaheim, CA, November 5, 2016, VERVE Symposium, Sydney, Australia, December 2, 2016

“How to Evaluate the Patient with Recurrent Varicose Veins/Venous Ulcers (Reflux sourcing)”, Gibson K, ACP Annual Congress, Anaheim, CA, November 4, 2016

“Avoiding Complications in Anticoagulation”, Gibson K, ACP Annual Congress, Anaheim, CA, November 4, 2016

“New Anticoagulants for the treatment of VTE-acute and extended therapy”, Gibson K, ACP Annual Congress, Anaheim, CA, November 4, 2016

“Can I Recognize Pelvic Etiology from the Clinical Examination?”, Gibson K, ACP Annual Congress, Anaheim, CA, November 3, 2016

“Chemical Ablation Techniques”, Gibson K, ACP Annual Congress, Anaheim, CA, November 3, 2016

”Liquid Sclerotherapy Basics”, Gibson K, VEINS at VIVA, Las Vegas, NV, September 18, 2016

”Management of Complex Reflux Patterns”, Gibson K, VEINS at VIVA, Las Vegas, NV, September 18, 2016

”Management of Pelvic Congestion Syndrome”, Gibson K, VEINS at VIVA, Las Vegas, NV, September 17, 2016

“Hormonal Influences on Venous Disorders”, Gibson K, West Coast Vein Forum, Monterey, CA, September 9, 2016

”Ultrasound guided foam for Truncal Veins, Tributaries, and Perforators”, Gibson K, West Coast Vein Forum, Monterey, CA, September 8, 2016

“Cyanoacrylate Closure of Incompetent Great, Small and Accessory Saphenous Veins without the use of Post-Procedure Compression: Initial Outcomes of a Post-Market Evaluation of the VenaSeal System (WAVES trial)-Preliminary One Month Data”, Gibson K, European Venous Forum, London, UK, July 8, 2016

“Nontumescent nonthermal technologies in the treatment of superficial venous insufficiency”, Gibson K, Venous Updates from the World, Universita di Ferrara, Italy, June 30, 2016

“Direct anticoagulants in the treatment of DVT/PE-is coumadin a thing of the past?” Gibson K, Congreso Del Bicentenario “Flebolinfo 2016”, Buenos Aires, Argentina, May 27, 2016

“A new era? Nontumescent technologies in the treatment of superficial venous insufficiency”, Gibson K, Congreso Del Bicentenario “Flebolinfo 2016”, Buenos Aires, Argentina, May 26, 2016

“Iliac stenting for thrombotic and nonthrombotic iliac stenoses”, Gibson K, Congreso Del Bicentenario “Flebolinfo 2016”, Buenos Aires, Argentina, May 26, 2016

“SECURE trial: Update on perforator ablation”, Gibson K, IVC, Miami, FL, April 28, 2016

“VeClose randomized clinical trial, 24 month follow-up results Veanseal v. RFA (ClosureFast)”, Gibson K, IVC, Miami, FL, April 28, 2016 and Congreso Del Bicentenario “Flebolinfo 2016”, Buenos Aires, Argentina, May 27, 2016

“Selection of patients for pelvic venous interventions: which patients to treat and which can be managed conservatively?” Gibson K, Charing Cross, London, UK, April 26, 2016

“VeClose Randomized Controlled Quality of Life (QOL) Assessment”, Gibson K, Charing Cross, London, UK, April 26, 2016

“Cyanoacrylate adhesive for the saphenous vein”, Gibson K, Venous Symposium, New York, NY, April 16, 2015

“Treatment of the small saphenous vein and its thigh extension”, Gibson K, Venous Symposium, New York, NY, April 16, 2016

“Early recurrence of leg varicosities and association with pelvic venous insufficiency”, Gibson K, Sedona Days, Carefree, Az, April 2, 2016

“Proprietary Microfoam”, Gibson K, American Venous Forum Summer Symposium, Orlando, Fl, February 24, 2016

“Perforator vein ablation: indications and treatment”, Asian Society of Vascular Surgery, Bangkok, Thailand, December 3, 2015

“Treatment algorithms for patients with venous disease: tailoring therapy to anatomy, pathology, and patient goals”, Gibson K, Asian Society of Vascular Surgery, Bangkok, Thailand, December 1, 2015

“Patient outcome measures: differences between endovascular and open surgical treatment of superficial venous disease”, Gibson K, Asian Society of Vascular Surgery, Bangkok, Thailand, December 1, 2015

“Veclose trial 12 month results”, Gibson K, VEITH symposium, New York, NY, November 19, 2015

“Step by step proprietary foam”, Gibson K, VEITH symposium, New York, NY, November 19, 2015

“Varicose veins with pelvic source and no pelvic symptoms-only need to treat the leg”, Gibson K, Venovisionaries at VEITH symposium, New York NY, November 18, 2015

“Saphenous reflux in patients with previous DVT”, Gibson K, AIM Symposium, New York, NY, November 16, 2015.

“Pros and cons of polidocanol endovenous microfoam”, Gibson K, AIM Symposium, New York, NY, November 16, 2015

“Wound care and compression therapy prior to treatment”, Gibson K, AIM Symposium, New York, NY, November 16, 2015

“Study design: types and differences”, Gibson K, American College of Phlebology Annual Meeting, Orlando, FL, November 14, 2015

“Conducting research in your office”, Gibson K, American College of Phlebology Annual Meeting, Orlando, FL, November 14, 2015

“Foam: Proprietary and physician compounded”, Gibson K, American College of Phlebology Annual Meeting, Orlando, FL, November 13, 2015

“Beyond ablation and sclerotherapy: expanding your vein practice into new areas”, Gibson K, American College of Phlebology Annual Meeting, Orlando, FL, November 12, 2015

“A changing landscape: top challenges for a phlebology practice”, Gibson K, American College of Phlebology Annual Meeting, Orlando, FL, November 12, 2015

“Endovenous microfoam ablation with Varithena: history, procedure, case studies”, “Varithena Polidocanol Injectable Foam”, Gibson K, Canadian College of Phlebology Meeting, Montreal, Canada, October 2, 2015

“Vulvar veins: cause of recurrence or missed source of varicose veins? Controversies in diagnosis and treatment”, Gibson K, SRRG meeting, Oberhofen, Switzerland, June 27, 2015

“Pelvic source veins of the perineum and vulva”, Gibson K, American Venous Forum West Coast Meeting, Napa, CA, May 2, 2015

“Hormonal influences on venous disorders”, Gibson K, American Venous Forum West Coast Meeting, Napa, CA, May 2, 2015

“Workup for DVT as a 1st event v. a recurrent event”, Gibson K, American Venous Forum West Coast Meeting, Napa, CA, May 1, 2015

“Sclerotherapy follow-up”, Gibson K, Venous Symposium, New York, NY, April 17, 2015

“Sclerotherapy selection: which ones and when”, Gibson K, Venous Symposium, New York, NY, April 17, 2015

“Venaseal ClosureSystem: clinical evidence” Gibson K, Medtronic sponsored dinner symposium at the Venous Symposium, New York, NY April 16, 2015

“Experience with endovenous microfoam”, Gibson K, Venous Symposium, New York, NY, April 16, 2015

“Evidence based management of calf vein thrombosis””, Gibson K, Venous Symposium, New York, NY, April 16, 2015

“Varithena-One Year After Launch”, Gibson K, Sedona Days, Sedona, Arizona, March 27, 2015

“What we know about recurrent varicose vein prevention: Is it disease progression?” Gibson K, American Venous Forum Annual Meeting, Palm Desert, Ca, February 26, 2015

“The Role of Ultrasound Imaging in Venous Disease”, Gibson K, Strandness Symposium, Honolulu, Hawaii, February 16, 2015

How I Decide Which Drug to use for Long Term Anticoagulation of DVT”, Gibson K, AIM Symposium, New York, New York, November 17, 2014

“Varithena: Indications, Technique, Patient Scheduling and Reimbursement Strategies”, Gibson K, AIM Symposium, New York, New York, November 17, 2014

“Treatment Effect of Polidocanol Injectable Foam 1% in Patients with Saphenofemoral Junction Incompetence: VANISH-2 One-Year Results”, Gibson K, American College of Phlebology Annual Congress, Phoenix, Arizona, November 7, 2014

“Using Good Science to Influence Chronic Venous Insufficiency Policy”, Gibson K, American College of Phlebology Annual Congress, Phoenix, Arizona, November 8, 2014

“Safety of Endothermal Ablation in the Patient on Anticoagulation”, Gibson K, American College of Phlebology Annual Congress, Phoenix, Arizona, November 7, 2014

“Pelvic Source Varicose Veins of the Vulva, Perineum and Thigh”, Gibson K, American College of Phlebology Annual Congress, Phoenix, Arizona, November 7, 2014

“Endothermal Ablation: When is Concomitant Therapy Appropriate?”, Gibson K, American College of Phlebology Annual Congress, Phoenix, Arizona, November 7, 2014

“Research in Private Practice”, Gibson K, American College of Phlebology Annual Congress, Phoenix, Arizona, November 7, 2014

“10 Things to Consider Before Opening Your Vein Practice”, Gibson K, American College of Phlebology Annual Congress, Phoenix, Arizona, November 6, 2014

“A Randomized, Controlled Trial Comparing Cyanoacrylate Adhesive Embolization with Radiofrequency Ablation for the Treatment of Incompetent Great Saphenous Veins: VeClose Study”, Gibson K, German Society of Phlebology, Munich, Germany, September 20, 2014

“Emerging Technologies in the Treatment of Superficial Venous Insufficiency”, Gibson K, CICE Annual Meeting, São Paulo, Brazil, April 25, 2014

“GSV Diameter Does not Correlate with Quality of Life Scores in Patients with GSV Incompetence”, Gibson K, CICE Annual Meeting, São Paulo, Brazil, April 23, 2014

“Embolization of the Great Saphenous Veins with Cyanoacrylate Adhesive”, Gibson K, Charing Cross Symposium, London, UK, April 7, 2014

“The Rationale for Treatment of the Small Saphenous and Perforator Veins” Gibson, K, CADECI Annual Meeting, Guadalajara, Mexico, February 22, 2014

“Laser Ablation: a Perspective After Ten Years Experience”, Gibson K, CADECI Annual Meeting, Guadalajara, Mexico, February 22, 2014

“How Varithena Improves Safety and Efficacy in Varicose Vein Management”, Gibson K, BTG sponsored Symposium at the American Venous Forum, New Orleans, LA, February 20, 2014

“Clinical Presentation of Women with Pelvic-Source Varicose Veins in the Perineum: First Steps in the Development of a Disease-Specific Patient Assessment Tool”, Gibosn K, Neradilek M, Minjarez R, Ferris B, Wise M, Meissner M, American Venous Forum Annual Meeting, New Orleans, LA, February 19, 2014 and European Venous Forum, Paris, France, June 2014

“Pelvic Venous Disorders”, Gibson K, Oklahoma University Health Sciences Center Invited Lecture, January 10, 2014

“The Nuts and Bolts of Setting up a Venous Center”, Gibson K, Gaspar Symposium, University of Southern California, Los Angeles, CA, September 25, 2013

“The Role of Residual Venous Thrombus in Determining Duration of Anticoagulation”, Gibson K, UIP World Meeting, Boston, MA, September 12, 2013

“*In Vitro and In Vivo* Performance of Physician-Compounded Foam v. Polidocanol Endovenous Microfoam”, Gibson K, Caurgo D, UIP World Meeting, Boston, MA, September 11, 2013

“Oral Direct Thrombin Inhibitors”, Gibson K, UIP World Meeting, Boston, MA, September 10, 2013

“Sclerotherapy Drugs, Including Proprietary Foam”, Gibson K, American College of Phlebology Advanced Sclerotherapy Course, Dallas, TX, May 18, 2013

“PEM Sclerotherapy Safety and Efficacy: Clinical Trial Update”, Gibson K, Society for Interventional Radiology Annual Scientific Meeting, New Orleans, LA, April 18, 2013

“Setting up a Venous Center”, Gibson K, Society for Interventional Radiology Annual Scientific Meeting, New Orleans, LA, April 18, 2013

“Calf Vein DVT: Treatment v. Surveillance”, Gibson K, Strandness Symposium 2013, Maui, Hawaii, January 22, 2013

“What is New in the Treatment Guidelines for DVT-ACCP and AHA”, Gibson K, Strandness Symposium 2013, Maui, Hawaii, January 22, 2013

“Duplex Scanning for Venous Ablation Procedures”, Gibson K, Strandness Symposium 2013, Maui, Hawaii, January 22, 2013

“Setting up a Venous Center”, Gibson K, Western Vascular Society Annual Meeting, Park City, Utah, September 24, 2012

“Clinical Aspects of Foam Sclerotherapy in the Treatment of Superficial Reflux”, Gibson K, American College of Phlebology Annual Congress, Hollywood, Florida, November 16, 2012

“Great Saphenous Vein (GSV) Diameter Correlation with Quality of Life Scores, CEAP classification, and Venous Clinical Severity Scores (VCSS) in Patients with GSV Incompetence”, Gibson K, Meissner M, Wright D, Wise M, American College of Phlebology Annual Congress, Hollywood, Florida, November 16, 2012

“Multicenter Evaluation of a Novel Patient Outcome Tool for Assessing Efficacy of Polidocanol Endovenous Microfoam (PEM) for Treatment of Symptomatic Visible Varicose Veins with Saphenofemoral Junction (SFJ) Incompetence: The ProtoSymQ Instrument”, Gibson K, Rush J, Evans E, Orfe E, King T, Wright D, European Venous Forum Annual Meeting, Florence, Italy, June 30, 2012

“Emerging Technologies in the Treatment of Superficial Venous Insufficiency”, Gibson K, Pacific Northwest Endovascular Conference, Seattle, WA, May 24, 2012

“Arterial Mapping: Is it Useful Prior to Endovascular Treatment?”, Gibson K, Vascular Lab 2012: Advanced Topics for Vascular Specialists and Other Health Care Professionals, UC Davis Health System, Sacramento, California, April 21, 2012

“Uncommon Venous Diseases in the Vascular Laboratory”, Gibson K, Vascular Lab 2012: Advanced Topics for Vascular Specialists and Other Health Care Professionals, UC Davis Health System, Sacramento, California, April 21, 2012

“Correlation of CEAP Clinical Class, Venous Clinical Severity Scores (VCSS), Vein Diameter, and Reflux Time in the Great Saphenous Vein (GSV) in Patients with Superficial Venous Insufficiency” Wise M, Gibson K, Western Vascular Annual Meeting, Kauai, Hawaii, September 20, 2011

“The Economics and Efficacy of Foam Sclerotherapy- Will it Replace Endovenous Ablation?” Gibson K, Pacific Northwest Endovascular Conference, Tacoma, Washington April 15, 2011

“Optimizing Your Vein Practice” Gibson K, , Pacific Northwest Endovascular Conference, Tacoma, Washington April 15, 2011

“Patient Characteristics, Referral Patterns and Associated Factors in Patients Referred to an Outpatient Vascular Laboratory to Rule Out Deep Venous Thrombosis” Gibson K, Polisar N, Nerdalik M, American Venous Forum Annual Meeting, San Diego, California, February 26, 2011 and American College of Phlebology Annual Congress, Hollywood, Florida November 16, 2011

“GSV Diameter Does not Correlate with Quality of Life Scores in Patients with GSV Incompetence”, Gibson K, Meissner M, Wright D, American Venous Forum Annual Meeting, San Diego, California, February 24, 2011

“Preoperative Vein Mapping”, Gibson K, Ebert A, Strandness Symposium, Wailea, Hawaii January 20, 2011

“Duplex Scanning for Ablation Procedures”, Gibson K, Ebert A, Strandness Symposium, Wailea, Hawaii January 18, 2011

“Expanding Your Venous Practice: Management of Acute DVT”, Gibson K, Society for Vascular Surgery Postgraduate Course, Boston, Massachusetts June 9, 2010

“Foam Sclerotherapy: Current Usage and Update on the Status of Clinical Trials”
Gibson K, Pacific Northwest Endovascular Conference, Tacoma, Washington
March 25, 2010

“The Business of DVT” Gibson, K; American College of Phlebology Annual
Clinical Congress, Palm Desert California, November 2009.

“Validating VEINES QOL/SYM” Gibson K, Morrison N, Munavall G, Regan J;
College of Phlebology Annual Clinical Congress, Palm Desert California,
November 2009, and European Venous Forum, Antwerp, Belgium, June 2010

“Foam Sclerotherapy” Annual Meeting of the American Venous Forum, Phoenix,
Arizona, February 2009.

“Proprietary Polidocanol Endovenous Microfoam (PEM) Bubble Embolization
Does Not Cause Cerebral Injury” American College of Phlebology Annual
Clinical Congress, Marco Island Florida November 2008.

“Endovenous Vein Treatment: Unanswered Questions,” Gibson K; Pacific
Northwest Endovascular Conference, Tacoma Washington, March 2008.

“Endovenous Laser Treatment of the Small Saphenous Vein: Efficacy and
Complications,” Gibson K, Ferris B, Polissar N, Neradilek B, Pepper D; Western
Vascular Society Annual Meeting, La Jolla, CA, September 2006.

"Laser Ablation of the Lesser Saphenous Vein: Complications and Short Term
Results," Gibson K, American College of Phlebology Annual Meeting, November
12, 2005.

"Women In Surgery: A Historical Perspective," Gibson K, Presented to WWAMI
students, Bozeman, MT, as part of medical history lecture series, April 2005.

"Incidence of Deep Venous Thrombosis After Laser Ablation of the Greater
Saphenous Vein," Gibson K, Pacific Northwest Vascular Society Annual
Meeting, November 2004.

"Laser Ablation of the Greater Saphenous Vein," Gibson K, Pacific Northwest
Vascular Society Annual Meeting, November 2004.

"Vascular Access Survival and Incidence of Revisions: United States Renal Data
System Dialysis Morbidity and Mortality Study (USRDS DMMS)," Gibson K,
Kohler T, Caps M, Gillen D, Sherrard D, Stehman-Breen C; Western Vascular
Society Annual Meeting, Couer d'Alene, ID, September 2000.

"Predictors of Limb Loss and Compartment Syndrome Following Lower Extremity Traumatic Arterial Injury," Gibson K, Meissner M, Karmy-Jones R; Western Vascular Society Annual Meeting, Couer d'Alene, ID, September 2000.

"Identification of Factors Predictive of Lower Extremity Vein Graft Thrombosis," Gibson K, Caps M, Bergelin R, Primozich J, Strandness DE, Jr., Society for Vascular Surgery Annual Meeting, Toronto, Canada, June 14, 2000.

"Assessment of a Policy to Reduce the Placement of Prosthetic Hemodialysis Access in a Veterans Health Care System," Gibson K, Caps M, Gillen D, Aldassy M, Kohler T, Hatsukami T, Sherrard D, Stehman-Breen C. Seattle Surgical Annual Meeting, January 2000; Association of VA Surgeons Annual Meeting, Seattle, WA, April 2000.

"Synthetic Femoral-Popliteal Bypass Grafts in 'Excellent Risk' Claudicants," Gibson K, Johansen K, Watson J, Western Vascular Society Meeting, Lake Tahoe, CA, September 1999.
Pacific Northwest Vascular Society Meeting, Vancouver, Canada, November 1999.

"The Surgical Management of Cardiac Arrest Due to Massive Pulmonary Embolus in Orthopedic Trauma Patients," Gibson K, Karmy-Jones R, Washington State Chapter of the American College of Surgeons, June 1998.

"Treatment of Iatrogenic Pseudoaneurysm with Percutaneous Ultrasound Guided Thrombin Injection," Gibson K, Caps M, Seattle Surgical Society Annual Meeting, January 1999.

"Aorto-iliac Occlusion Caused by Paradoxical Embolism," Gibson K, Seattle Surgical Meeting, January 1995

"Trauma and the Rural Surgeon," Gibson K, Rinker C, Annual Meeting of the Montana/Wyoming chapter of the American College of Surgeons. 1992

CLINICAL TRIALS

Arterial Trials:

Principal Investigator, Bellevue Site, CREST II, sponsored by National Institutes of Health/Mayo Clinic, November 2015-present

Principal Investigator, Bellevue Site, Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS), sponsored by Bayer, September 2014-present

Investigator, Bellevue Site, Mechanisms of Arterial Graft Healing, sponsored by the National Institutes of Health/University of Washington, August 2012-present

Dialysis Access Trials:

Sub-Investigator, Bellevue Site, A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula (AVF) Creation in Patients with Chronic Kidney Disease (CKD) PATENCY-2, sponsored by Proteon, January 2016-present

Sub-Investigator, Bellevue Site, A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula (AVF) Creation in Patients with Chronic Kidney Disease (CKD), sponsored by Proteon, August 2014-present

Hemostasis Trials:

Sub-Investigator, Bellevue Site, Effectiveness and Safety of CELSTAT for Hemostasis in Intraoperative Tissue Bleeding, sponsored by Baxter Healthcare Corporation, February 2016-present

Principal Investigator, Bellevue Site, Phase III TC-2402-039-SP trial. randomized, open label, parallel-Group, multi-center Trial to compare efficacy and safety of TachoSil® versus Surgicel® original for the secondary hemostatic treatment of needle hole bleeding in vascular surgery, sponsored by Takeda Nycomed, February 2012-2016

Principal Investigator, Bellevue Site, Phase III, Randomized, Single-Blind, Controlled Trial of Topical Fibocaps in Intraoperative Surgical Hemostasis, Sponsored by ProFibrix, Inc. June 2012-July 2013

Principal Investigator, Bellevue and Kirkland Site, Phase III Clinical Evaluation of Efficacy and Safety of FS VH S/D for Hemostasis in Subjects Undergoing Vascular Surgery, sponsored by Baxter Healthcare Corporation, July 2010-December 2010

Thromboembolism Trials:

Principal Investigator, Bellevue Site, EINSTEIN CHOICE: sponsored by Bayer, October 2015-present

Principal Investigator, Bellevue Site, Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation, sponsored by Iverson Genetics Diagnostics, Inc, November 2011-September 2015

Principal Investigator, Bellevue Site, Phase III AMPLIFY trial (Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism), sponsored by Bristol Myers Squibb/Pfizer, November 2010-2012

Principal Investigator, Bellevue Site, Phase III AMPLIFY-EXT trial (Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism), sponsored by Bristol Myers Squibb/Pfizer, November 2010-December 2012

Principal Investigator, Bellevue Site, Phase III RECOVER trial (Dabigatran etexilate versus coumadin for acute symptomatic venous thromboembolism), sponsored by Boehringer Ingelheim, March 2009-September 2010

Principal Investigator, Bellevue Site, Phase III RESONATE trial (Dabigatran etexilate versus placebo in the long term prevention of recurrent symptomatic venous thromboembolism), sponsored by Boehringer Ingelheim, March 2009-December 2010

Varicose Vein Trials:

Principal Investigator, WAVES: Lake Washington Vascular VenaSeal Post-Market Evaluation, Investigator driven with grant from Medtronic, October 2015-present.

Principal Investigator, Bellevue and Kirkland site, COMFORT: A Multicenter, Open-label, Randomized Cross-over Study to Evaluate Pain Following Treatment of Varicose Vein With Varithena Compared to Radiofrequency Ablation, sponsored by BTG, June 2015-present.

Principal Investigator, Bellevue Site, Prospective Safety and Effectiveness Study: VenaCURE Endovenous Laser Treatment Fiber Procedure Kit for Treatment of Incompetent Perforator Veins, sponsored by Angiodynamics, October 2014-present.

Principal Investigator, Bellevue site, Randomized Control Trial Comparing VenaSeal Saphenon Closure System With Radiofrequency Ablation, Sponsored by Saphenon, March 2013-present

Principal Investigator, A Comparison of Specialized versus Standard Compression After Saphenous Ablation (COSSCA Trial), Sponsored by Sigvaris, May 2012-November 2012

Principal Investigator, Bellevue and Kirkland Site, Phase III Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities (017), sponsored by BTG, April 2011-June 2012

Principal Investigator, Bellevue Site, Phase III Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence (VANISH-2) , sponsored by BTG, November 2010-November 2011

Principal Investigator, Bellevue Site, Phase III Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence (VANISH-2) Extension Trial, sponsored by BTG, November 2011-2014

Principal Investigator, Bellevue Site, Phase III An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins , sponsored by BTG, July 2009-September 2010

Principal Investigator, Bellevue Site, Phase III Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Endovenous Microfoam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence (Pilot), sponsored by BTG, October 2008-September 2009

Principal Investigator, Bellevue Site, Savvy Trial (Study of Appearance and Symptom Improvement following Treatment of Varicose Veins), sponsored by BTG, July 2008-April 2009

Principal Investigator, Bellevue Site, Phase II Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt (MRI), sponsored by BTG, January 2007-July 2009

Sub-Investigator, RELIEVE Trial, sponsored by Vascular Solutions, June 2007-2008 (laser closure of perforator veins)

Venous Stent Trials:

Sub-Investigator, VERNACULAR Trial, sponsored by Bard, October 2016-present (venous stents for iliac venous disease)

Venous Ulcer Trials:

Principal Investigator, Bellevue Site, HP 802-247-09-015 Phase II venous ulcer trial to determine the effectiveness of two dosing frequencies and two different concentrations of HP802-247, together with standard care, compared to placebo, plus standard care, sponsored by Healthpoint, February 2010-February 2011

Principal Investigator, Bellevue Site, HP 802-247-09-016 Phase II trial examines the durability of previous target wound closures, identify new test article-related adverse events, record new target wound closures, and examine ongoing adverse events not resolved in subjects who participated in HP 802-247-09-015, sponsored by Healthpoint, February 2010-June 2011

HONORS AND ORGANIZATIONS

- * Society of Vascular Surgery
- * American Venous Forum
- * American College of Phlebology
- * European Venous Forum
- * Western Vascular Society
- * Pacific Northwest Vascular Society
- * Fellow, American College of Surgeons
- * Alpha Omega Alpha
- * Henry Harkins Society
- * Washington State Medical Association

Clinical Practice:

- *Named a Seattle Metropolitan Magazine “Top Doctor” 2010, 2013, 2014, 2015, 2016, 2017
- * Named a Seattle Magazine “Top Doctor” 2007, 2008, 2009, 2013, 2015, 2017
- * Bronze Award, Abstract American College of Phlebology November 2008, November 2012
- * Distinguished Fellow, American Venous Forum, Received February 2016
- * Elected “Honorary Member”, Congreso del Bicentenario Flebolinfo 2016, by the organizing three joint phlebologic societies, Buenos Aires, Argentina

Residency/Fellowship:

- * Best Clinical Paper, Seattle Surgical Annual Meeting, January 2000
- * Housestaff Award, Harborview Medical Center, 1998-1999
- * Alpha Omega Alpha

Medical School:

- * Alpha Omega Alpha, one of five in class elected in junior year
- * James W. Haviland Award
- * Graduated with Highest Honors, Graduated first in Medical School Class

High School:

- * Valedictorian, National Merit Scholar